Clinical Research Directory
Browse clinical research sites, groups, and studies.
TMS Pilot in Early AD II
Sponsor: HealthPartners Institute
Summary
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion. AD is functionally characterized by progressive degeneration of large-scale brain networks (LSBNs), including the default mode network (DMN) presumably from the deposition of amyloid plaques and neurofibrillary tangles. Available FDA-approved medications for AD such as donepezil and memantine offer limited benefit and modest impact on quality of life. Transcranial magnetic stimulation (TMS) with intermittent theta burst stimulation (iTBS) offers a non-invasive alternative to pharmacotherapy in persons with AD. We propose a case series study to compare sham with iTBS.
Official title: A Preliminary Sham-Controlled Theta Burst Stimulation (TBS) Study in Early-Stage Alzheimer's Disease (AD)
Key Details
Gender
All
Age Range
40 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2024-12-23
Completion Date
2026-12
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
Intermittent theta burst stimulation active coil
MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
Sham coil
MagVenture TMS Therapy sham coil
Locations (1)
HealthPartners Neuroscience Center
Saint Paul, Minnesota, United States